How effective and effective is dexmethylphenidate (Azstarys)

Dexmethylphenidate (Azstarys) is a new central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD). It was approved by the US FDA in 2021. This medicine consists of two ingredients: dexmethylphenidate (d-methylphenidate) and its prodrug serdexmethylphenidate (abbreviationSDX). The innovative design of this two-component combination is that the drug can achieve a dual drug release mode of "immediate release + sustained release", allowing the blood drug concentration to rise rapidly and maintain stability after taking the drug, thereby effectively improving the concentration and behavioral control problems of ADHD patients and reducing early and late drug effect fluctuations.

Clinical observations show that the therapeutic effect of dexmethylphenidate in school-age children and adolescents is similar to or even better than traditional methylphenidate preparations. Its core advantage is that the drug effect lasts longer and can cover the entire study or workday without the need for refills midway. For patients with heavy academic workload or short attention span, this can significantly reduce problems such as decreased concentration, anxiety or irritability caused by the weariness of the drug effect. Compared with some short-acting methylphenidate preparations, dexmethylphenidate has a faster onset of action and is better tolerated. Some studies have pointed out that it can exert a significant cognitive and behavioral improvement effect about about 30 minutes after taking it.

In addition, dexmethylphenidate showed stable performance in improving impulse control, learning concentration and task execution ability. Many parents and clinicians report that the drug not only improves their children's attention in class, but also improves social adjustment and family interactions. This stable drug effect is mainly attributed to the sustained-release mechanism of the prodrug, which can be gradually converted into dexmethylphenidate in the body, thereby providing a sustained central stimulation effect and avoiding the "drug rebound" phenomenon caused by a sudden drop in drug effect.

In terms of safety, dexmethylphenidate was generally well tolerated. The most common adverse reactions include mild insomnia, decreased appetite, mild headache, or stomach upset, which usually diminish gradually early in treatment. Because its pharmacological mechanism is similar to that of methylphenidate, some patients may need their doctor to adjust the dose based on individual response to achieve the best balance.

Reference materials:https://azstarys.com/